GlobeNewswire

Auriant Mining AB (publ.) publishes January-December 2020 Interim Report

Share

Financial Highlights

•   Consolidated revenue was MSEK 492.1 (US$ 53.4 mln), up 79% YoY (2019: MSEK 281.6 (US$ 29.8 mln)).

•   Net profit after tax amounted to MSEK 96.5 (US$ 10.7 mln) compared to loss of MSEK -6.0 (US$ -1.2 mln) in 2019.

•   Strong increase in EBITDA: in 2020 EBITDA amounted to MSEK 283.0 (US$ 30.9 mln) compared to MSEK 68.2 (US$ 7.2 mln) in the previous year.

•   Net cash flow generated from operating activities was MSEK 251.2 (US$ 27.5 mln), up 315% YoY (2019: MSEK 84.9 (US$ 8.9 mln)).

Operational Highlights

•   Volume of ore processed through the CIL plant amounted to 394 thousand tonnes with an average grade of 2.66 g/t (total gold in processed ore – 1,045 kg). The CIL plant was operating at projected throughput per working hour (>50 t/hour) and higher recovery rate (91%).

•   Hard rock gold production at Tardan increased by 50%, from 635 kg (20,407 oz) in 2019 on the heap leach and CIL to 953 kg (30,629 oz) in 2020 on CIL. 

•   Alluvial gold production decreased by 78% to 12 kg (386 oz) compared to 54 kg (1,730 oz) in 2019.

•   Total gold production was 965 kg (31,014 oz), up 40% YoY (2019: 689 kg (22,137 oz)).

•   Average selling price for gold increased by 24% to US$ 1,755 per oz (2019: US$ 1,416 per oz).

•   Total Cash cost reduced by 24% to US$ 676 per oz (2019: US$ 884 per oz).

•   In April 2020, the Group restructured repayment terms of existing loans provided by VTB rolling them over until end of 2023. In July 2020, the Group extinguished its loans in the amount of MSEK 23.2 (US$ 2.6 mln), which were raised in connection with the CIL plant financing in 2018-2019. In October 2020, the Group negotiated with VTB a reduction in interest rate applying to outstanding balance. As from 21 October 2020, the new interest rate is 3 months LIBOR plus 4.7% (currently equivalent to an annual interest rate of 4.9%).

•   2021 annual total gold production forecast is 900 - 930 kg (28,936 – 29,900 oz). Annual throughput of the CIL plant will amount to 350 - 380 thousand tonnes.

Full report is available here

This will be followed by a ZOOM Conference for analysts and investors with Danilo Lange (CEO), Vladimir Vorushkin (CFO) and Petr Kustikov (COO), who will be presenting Auriant Mining’s Q4 2020 results as well as hosting a Q&A session.

The event will begin at 12:00 CET (12:00 Stockholm, 14:00 Moscow, 11:00 London).

To participate in a ZOOM Conference on Friday, February 26th, please send to our email conf@auriant.com the following information: email, name, Company name. We will send the conference ID and passcode by email.

For more information please contact:

Danilo Lange, CEO
Tel: +7 495 109 02 82
E-mail: d.lange@auriant.com

Company name: Auriant Mining AB
Short name: AUR
ISIN-code: SE0001337213

Website: www.auriant.com
www.facebook.com/AuriantMining/

Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in Zabaikalye and the Republics of Khakassia and Tyva. The company has currently four assets, including two operating mines (Tardan and Solcocon), one early stage exploration asset and one development asset.

Since July 19, 2010, Auriant Mining´s shares are traded on Nasdaq First North Premier Growth Market under the short name AUR. For more information please visit www.auriant.com. Mangold Fondkommission is Certified Adviser to Auriant, for more information please call +46 8 503 015 50, e-mail CA@mangold.se or visit www.mangold.se.

This information is information that Auriant Mining AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07.00 CET on February 26th, 2021.

Cautionary Statement: Statements and assumptions made in this report with respect to Auriant Mining AB’s (“AUR”) current plans, estimates, strategies and beliefs, and other statements that are not historical facts, are forward-looking statements about the future performance of AUR. Forward-looking statements include, but are not limited to, those using words such as "may", "might", "seeks", "expects", "anticipates", "estimates", "believes", "projects", "plans", strategy", "forecast" and similar expressions. These statements reflect management's expectations and assumptions in light of currently available information. They are subject to a number of risks and uncertainties, including, but not limited to, (i) changes in the economic, regulatory and political environments in the countries where AUR operates; (ii) changes relating to the geological information available in respect of the various projects undertaken; (iii) AUR’s continued ability to secure enough financing to carry on its operations as a going concern; (iv) the success of its potential joint ventures and alliances, if any; (v) exchange rates, particularly between the Russian rouble and the U.S. dollar. In the light of the many risks and uncertainties surrounding any gold production and exploration company at an early stage of its development, the actual results could differ materially from those presented and forecast in this report. AUR assumes no unconditional obligation to immediately update any such statements and/or forecasts. This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions. Nothing in this press release should be considered as an offer to invest or otherwise trade in shares of Auriant Mining AB (publ). The proposed issue will not be directed at residents or those living in the United States, Australia, Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action would require further prospectus, other offering documentation, registration or other measures beyond those required by Swedish law. No securities will be registered under the United States Securities Act of 1933, a similar law in any state in the United States, or under any provincial law in Canada, nor under the applicable law of another country.

Attachments


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million23.4.2021 07:00:00 CEST | Press release

GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million Schiphol, the Netherlands – 23 April 2021. GrandVision N.V. publishes its First Quarter 2021 trading update. Due to the exceptional nature of the year 2020, GrandVision will also include in the present press release comparisons versus 2019. Highlights • GrandVision continues to show resilience in the first quarter despite the most recent COVID-19 related government restrictions in Europe and Latam • At constant exchange rates, revenue declined by -0.7% compared with 1Q20 to €899 million from €926 million in 1Q20 (1Q19: €974m) • Comparable revenue declined by -1.5% versus 1Q20 and on a 2019 basis, -10.8% versus 1Q19 • Adj. EBITA increased by 98.1% at constant exchange rates to €79 million from €41 million in 1Q20 (1Q19: €107m). Continued cost discipline, structural improvements in certain territories and improved product and price mix contributed to the underlying performance • Adj. EBITA margin at 8.8%,

Corbion appoints Aurélie Dalbiez as Chief Human Resources Officer23.4.2021 07:00:00 CEST | Press release

Corbion announces the appointment of Aurélie Dalbiez as Chief Human Resources Officer and member of the Executive Committee as of 1 July 2021. Mrs. Dalbiez (a French national) currently is Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career at Deutsche Bank before working for Capital International, a global investment company. CEO Olivier Rigaud commented: "I am really pleased to welcome Aurélie to the ExCo team as a seasoned HR leader who partners closely with the business to develop talent, drive culture, engagement, continuous improvement, and customer intimacy. Her appointment will also further enhance the diversity of our ExCo." Mrs. Dalbiez brings a multi-cultural background and perspective. She lived in the United States as a child, earned her university degree in International Business in Lyon, France and worked internationally throughout

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy23.4.2021 07:00:00 CEST | Press release

About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly)Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a specific therapy Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. Endometrial cancer is the most common gynecologic can

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies23.4.2021 06:01:00 CEST | Press release

Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis Mechelen, Belgium;23April 2021;06.01 CET; –Galapagos NV (Euronext & Nasdaq: GLPG) today report that their collaboration partnerGilead Sciences K.K. (“Gilead”) and Eisai Co., Ltd. (“Eisai”)today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis (UC).Filgotinib is a new oral Janus kinase (JAK) inhibitor approved in Japan in September 2020 for the treatment of rheumatoid arthritis. This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study evaluating the efficacy and safety of filgotinib for the induction and maintenance of remission in patients with moderately to severely active ulcerative colitis who have had a

Camposol Holding PLC Invitation to the Presentation of Fourth Quarter and Audited Full Year 2020 Financial Results23.4.2021 02:00:00 CEST | Press release

Camposol Holding PLC will announce the results for the full year 2020 on Thursday, April 29, 2021. In connection with the release, a telephone conference will be held at 9:30 a.m. (Lima) as described below. The presentation will be published at 8:30 a.m. (Lima) and will be available on the Company's website. In connection with the earnings release Samuel Dyer Coriat, CEO, and Andrés Colichón Sas, CFO, will host a conference call presentation and a Q&A session at 9:30 a.m. (Lima). To participate in the conference call, please use the following numbers: London, UK Local +0800 028 8438 US/Canada International +1 409 981 0728 Zurich, Switzerland, Local +044 580 1740 Oslo, Norway, Local +47 8001 6162 Colombia, National Free Phone +01 800 518 5094 Chile, National Free Phone +56 800 914 686 Peru, National Free Phone +51 0800 71470 Participants will be asked for their name and conference ID. The Camposol conference ID is: 2466977 Audio access for the meeting is available by dialing the above-m

CrossAmerica Partners LP Maintains Quarterly Distribution22.4.2021 22:30:00 CEST | Press release

•Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 Allentown, PA, April 22, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250per unit attributable to the firstquarter of 2021 ALLENTOWN, PA (April 22, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 11, 2021 to all unitholders of record on May 4, 2021. CrossAmerica will host a conference call on May 11th at 9:00 a.m. Eastern Time to discuss first quarter earnings results, which will be released after the market closes on Monday, May 10. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator, and owner and